NO20033192D0 - Fremgangsmåte for behandling av dopamin-relaterte dysfunksjoner - Google Patents
Fremgangsmåte for behandling av dopamin-relaterte dysfunksjonerInfo
- Publication number
- NO20033192D0 NO20033192D0 NO20033192A NO20033192A NO20033192D0 NO 20033192 D0 NO20033192 D0 NO 20033192D0 NO 20033192 A NO20033192 A NO 20033192A NO 20033192 A NO20033192 A NO 20033192A NO 20033192 D0 NO20033192 D0 NO 20033192D0
- Authority
- NO
- Norway
- Prior art keywords
- related dysfunctions
- treating dopamine
- dopamine
- treating
- dysfunctions
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229960003638 dopamine Drugs 0.000 title 1
- 230000004064 dysfunction Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26188901P | 2001-01-16 | 2001-01-16 | |
| PCT/US2002/001058 WO2002056875A2 (en) | 2001-01-16 | 2002-01-16 | Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20033192D0 true NO20033192D0 (no) | 2003-07-14 |
| NO20033192L NO20033192L (no) | 2003-07-14 |
Family
ID=22995315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20033192A NO20033192L (no) | 2001-01-16 | 2003-07-14 | Fremgangsmåte for behandling av dopamin-relaterte dysfunksjoner |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6916823B2 (no) |
| EP (1) | EP1351690A2 (no) |
| JP (1) | JP2005504717A (no) |
| KR (1) | KR20030070601A (no) |
| CN (1) | CN1499968A (no) |
| BR (1) | BR0206402A (no) |
| CA (1) | CA2434736A1 (no) |
| MX (1) | MXPA03006265A (no) |
| NO (1) | NO20033192L (no) |
| WO (1) | WO2002056875A2 (no) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10066158B4 (de) * | 2000-08-24 | 2007-08-09 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms |
| DE10053397A1 (de) | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
| CA2529528A1 (en) | 2003-06-20 | 2004-12-29 | Ronald Aung-Din | Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
| US20050171139A1 (en) * | 2003-10-07 | 2005-08-04 | Hammer Ronald P.Jr. | Treating psychotic symptoms |
| JP2007516292A (ja) * | 2003-12-23 | 2007-06-21 | ダーファーマ，インコーポレイテッド | ドーパミン受容体結合化合物の共投与 |
| WO2006012640A2 (en) * | 2004-07-21 | 2006-02-02 | Darpharma, Inc. | Method of administration of dopamine receptor agonists |
| US20100150839A1 (en) * | 2005-02-04 | 2010-06-17 | Massachusetts Institute Of Technology | Compositions and Methods for Modulating Cognitive Function |
| EP2010541A2 (en) * | 2006-02-21 | 2009-01-07 | Purdue Research Foundation | Trans-fused chromenoisoquinolines, synthesis and methods for use |
| US9066903B2 (en) * | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
| EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
| GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
| CA2729346A1 (en) * | 2008-06-30 | 2010-01-14 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
| US20110190332A1 (en) * | 2008-08-05 | 2011-08-04 | Effipharma | Dopamine receptor ligands with enhanced duration of action |
| US9359303B2 (en) | 2009-04-21 | 2016-06-07 | Purdue Research Foundation | Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor |
| KR101850889B1 (ko) * | 2014-07-09 | 2018-04-20 | 삼성에스디아이 주식회사 | 화합물, 이를 포함하는 유기 광전자 소자 및 표시장치 |
| US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
| JP2018507262A (ja) | 2015-03-02 | 2018-03-15 | アフギン ファーマ, エルエルシーAfgin Pharma, Llc | カンナビノイドを用いた、局所局部的神経作用療法 |
| US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
| CN107308135A (zh) * | 2017-06-26 | 2017-11-03 | 上海华迪机械有限公司 | 水凝胶贴剂制作工艺 |
| EP3745862B1 (en) * | 2018-01-31 | 2024-06-26 | Mayo Foundation for Medical Education and Research | D1 dopamine receptor agonists for treating fibrotic pathologies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744476A (en) * | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| BR9610323A (pt) * | 1995-08-18 | 1999-12-21 | Perdue Research Foundation | Novas isoquinolinas fundidas como ligantes de receptor de dopamina |
| US6733797B1 (en) * | 2000-11-15 | 2004-05-11 | William K. Summers | Neuroceutical for improving memory and cognitive abilities |
-
2002
- 2002-01-16 JP JP2002557383A patent/JP2005504717A/ja active Pending
- 2002-01-16 KR KR10-2003-7009268A patent/KR20030070601A/ko not_active Ceased
- 2002-01-16 WO PCT/US2002/001058 patent/WO2002056875A2/en not_active Ceased
- 2002-01-16 CA CA002434736A patent/CA2434736A1/en not_active Abandoned
- 2002-01-16 EP EP02707484A patent/EP1351690A2/en not_active Withdrawn
- 2002-01-16 MX MXPA03006265A patent/MXPA03006265A/es not_active Application Discontinuation
- 2002-01-16 US US10/050,289 patent/US6916823B2/en not_active Expired - Fee Related
- 2002-01-16 BR BR0206402-2A patent/BR0206402A/pt unknown
- 2002-01-16 CN CNA028037391A patent/CN1499968A/zh active Pending
-
2003
- 2003-07-14 NO NO20033192A patent/NO20033192L/no not_active Application Discontinuation
-
2005
- 2005-06-13 US US11/151,145 patent/US20050232870A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002056875A2 (en) | 2002-07-25 |
| WO2002056875A3 (en) | 2003-04-24 |
| KR20030070601A (ko) | 2003-08-30 |
| NO20033192L (no) | 2003-07-14 |
| BR0206402A (pt) | 2006-01-17 |
| JP2005504717A (ja) | 2005-02-17 |
| US20020132827A1 (en) | 2002-09-19 |
| MXPA03006265A (es) | 2004-06-25 |
| US6916823B2 (en) | 2005-07-12 |
| US20050232870A1 (en) | 2005-10-20 |
| EP1351690A2 (en) | 2003-10-15 |
| CA2434736A1 (en) | 2002-07-25 |
| CN1499968A (zh) | 2004-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20033192D0 (no) | Fremgangsmåte for behandling av dopamin-relaterte dysfunksjoner | |
| NO20030241D0 (no) | Fremgangsmåte for behandling av multiple brönnintervaller | |
| NO20032172L (no) | Fremgangsmåte ved behandling av underjordisk formasjon | |
| NO20030265L (no) | Fremgangsmater ved behandling av borebronner | |
| NO20034399D0 (no) | Fremgangsmåte og anordning for styring av aksess til spillemaskinområder | |
| NO20025814D0 (no) | Fremgangsmåte ved brönnfullföring | |
| FI20000863L (fi) | Uusi hoitomenetelmä | |
| NO20014221D0 (no) | Fremgangsmåte for behandling av anstrengelses-indusert astma | |
| FI20011581L (fi) | Menetelmä ja laitteisto vesienergian hyödyntämiseksi | |
| FI20012170L (fi) | Menetelmä lauhteiden käsittelemiseksi | |
| EE200400068A (et) | Meetod ja seade orgaanilise materjali töötlemiseks | |
| NO334788B2 (no) | Fremgangsmåte for behandling av søvnløshet | |
| NO20014222L (no) | Fremgangsmåte for behandling av COPD | |
| DE50202698D1 (de) | Beschichtungsverfahren | |
| NO20015162D0 (no) | Fremgangsmåte for behandling av nevrodegenerering | |
| DE50208867D1 (de) | Beschichtungsverfahren | |
| IL161630A0 (en) | Methods of treating endometreosis | |
| NO20042139L (no) | Fremgangsmate for behandling av hyperaktiv blaere | |
| GB0211914D0 (en) | Method of pattern discovery | |
| SE0104249D0 (sv) | Method of treatment | |
| FI20020911A0 (fi) | Menetelmä ja laitteisto puun kuumakuivaamiseksi tai lämpökäsittelemiseksi | |
| SE0104471D0 (sv) | New method | |
| NO20011136D0 (no) | FremgangsmÕte ved byggbehandling | |
| NO20000975D0 (no) | Metode og anordning for hindring av beleggdannelse | |
| SE0102777D0 (sv) | New method and apparatus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |